Member Info for Ctw2014

John Meyer ore GEO on today’s podcast very positive. ‘All to play for and looking good’ copper resource could be worth ‘billions of dollars’ etc etc

That delayed buy which just showed up on LSE is one of a long series of big round number buys. Someone is quietly loading up.

Hi Troy The thing is at least Odey do not appear to be selling in the open market. As long as that persists (with the Pru taking up any that Odey do sell) it should not affect the share price. As we have seen, it only takes a few buys to move this up quite quickly. For all we know Odey could be happy to hold their remaining share holding. On balance, and ever the optimist, I am more encouraged that the Pru are growing their stake than discouraged that Odey reduced theirs. If a) the commercial sales of the HCV test which we know have begun go well and/or b) the Services Division, which is exclusive negotiations with a buyer, is pulled off, I believe we will get a significant boost. Genedrive are attending conferences in Singapore and Paris on 2-4 and 11-15 April which could generate more PR and, hopefully, more buys!

Nice to see the MMs move this up on the back of the RNS re the India distribution deal. All we need now is some actual buys!

They could do with more PR Truro. Not enough people know about it. Seems to be a gradual pick up in interest though.

Aha, Odey reducing explains how the Pru increased their stake by 2.66% of the Company without the sp going through the roof. They bought them from Odey rather than on the open market. That’s what it looks like to me anyway. The numbers tally.

Not a bad set of results in my view. £3.9m cash left at end of February. Revenue down slightly by £0.3m on first half of last year but loss reduced by £0.8m to £2.2m. Genedrive revenues up by 8.3% and although existing sponsored DoD and Aquaculture programmes are coming to an end, the potential still exists for further revenues arising from these albeit that none is currently projected. The main short term revenue driver is the HCV kit which we know has commenced first commercial sales with the distributor and ‘is rapidly becoming available in target countries’. Update on a date for launch of version 2 of the TB test not expected until 2019. However, exciting to note that they expect one definitive new application within the human genotype arena to be announced within the current financial year. Even better, note that they say that they are in a period of exclusivity with a prospective buyer for the Services Division and expect to announce the outcome before the end of the year. If they pull of a sale this will provide a significant cash boost which will help fund the company whilst revenues from the Genedrive applications grow. All in all quite promising imo.

Yes, possibly people buying in ahead of the results tomorrow. Although we are only a week away from the last RNS on initial commercial sales of the HCV kit, it will be interesting to see if the results include more detail on that.

Plenty of cash in the bank to progress the DFS. Just a waiting game here.

Sell price is 9.08 so quite a few buys showing as sells.

Clearly most holders were expecting a final agreement, not merely an MOU, and the last update was grounds for expecting that. So in that rather large sense it’s a disappointment, hence the sell off. On the other hand we now have a 50% funding agreement, which will slow the cash burn and allow us to make progress. There is now predictable news flow, including the publication of a JORC resource, so my bet is that this will recover in fairly short order. Cheesed off to be even further under water, but not selling down here.

.....just paid.

.......people are gradually beginning to take note of the potential here. Nice £37k buy just in.

Great news indeed

I don’t know that it’s the market makers fault. They are just doing what they do in response to supply and demand. Demand is weak and has been for a while because PIs are getting anxious about the delay and in some cases jumping ship (quite likely at a loss) releasing cheap shares for those with a bigger appetite for risk. We know that at least one PI has been accumulating a large holding (see last TR1). Personally I only have a small holding and, whilst unhappy to be under water with it, am prepared to take the risk and hold in the expectation that finalisation of the deal will be announced soon. There have been a lot of posts lately talking the share down (just as there was prior to the last rise in the sp) but imo it’s all just noise from people no more in the know than the rest of us.

....£41k buy popped up.

Some massive delayed buys from 1st March - £400k worth in 3 trades. Something leaked?

HCV not HIV!

The RNS talks about a 1 year development programme followed by performance and clinical validation. The funding runs until end of June 2919, so I don’t see it getting to market before then. The HIV test remains the near term driver.

Indeed, which is that after a long decline because of various delays, we hit bottom at 7.25p in October. Having completed the factory and started building the order book/sales we have begun the long climb back up. Lack of news has caused the SP to drop back a bit from the recent high, but news of a new deal or similar could drop at any time.